{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CNY", "shortName": "INNOCARE PHARMA LTD", "messageBoardId": "finmb_643357876", "exchangeTimezoneShortName": "CST", "market": "cn_market", "gmtOffSetMilliseconds": 28800000, "esgPopulated": false, "exchange": "SHH", "longName": "InnoCare Pharma Limited", "regularMarketChangePercent": 0.65076035, "regularMarketPrice": 13.92, "exchangeTimezoneName": "Asia/Shanghai", "marketState": "POSTPOST", "regularMarketChange": 0.09000015, "regularMarketTime": 1683874802, "regularMarketDayHigh": 14.32, "regularMarketDayRange": "13.81 - 14.32", "regularMarketDayLow": 13.81, "regularMarketVolume": 5587497, "regularMarketPreviousClose": 13.83, "bid": 13.92, "ask": 13.93, "fullExchangeName": "Shanghai", "financialCurrency": "CNY", "regularMarketOpen": 13.85, "averageDailyVolume3Month": 8124352, "averageDailyVolume10Day": 5280226, "fiftyTwoWeekLowChange": 5.21, "fiftyTwoWeekLowChangePercent": 0.598163, "fiftyTwoWeekRange": "8.71 - 16.99", "fiftyTwoWeekHighChange": -3.0699997, "fiftyTwoWeekHighChangePercent": -0.1806945, "fiftyTwoWeekLow": 8.71, "fiftyTwoWeekHigh": 16.99, "earningsTimestamp": 1683625795, "earningsTimestampStart": 1683625795, "earningsTimestampEnd": 1683625795, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.65, "epsForward": -0.22, "epsCurrentYear": -0.34, "priceEpsCurrentYear": -40.941177, "sharesOutstanding": 0, "bookValue": 4.531, "fiftyDayAverage": 12.705, "fiftyDayAverageChange": 1.2150002, "fiftyDayAverageChangePercent": 0.09563165, "twoHundredDayAverage": 13.298839, "twoHundredDayAverageChange": 0.62116146, "twoHundredDayAverageChangePercent": 0.046707947, "marketCap": 13639526400, "forwardPE": -63.272728, "priceToBook": 3.0721693, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1663723800000, "priceHint": 2, "symbol": "688428.SS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building 8", "address2": "No. 8 Life Science Park Road Zhongguancun Life Science Park Changping District", "city": "Beijing", "zip": "102206", "country": "China", "phone": "86 10 6660 9999", "fax": "86 10 6070 2992", "website": "https://www.innocarepharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jisong  Cui Ph.D.", "age": 59, "title": "Co-Founder, Exec. Chairperson & CEO", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 7487000, "fmt": "7.49M", "longFmt": "7,487,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Renbin  Zhao Ph.D.", "age": 53, "title": "VP of Regulatory Affairs & Clinical Devel. and Exec. Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 2906000, "fmt": "2.91M", "longFmt": "2,906,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Nan  Gao", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Xiangyang  Chen Ph.D.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Junsu  Wang", "age": 46, "title": "Gen. Counsel", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Xiaodong  Jin", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Xiang-Yang  Zhang", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Davy  Ouyang Ph.D.", "title": "VP & Head of Biology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Pui Shan  Lee", "title": "Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James  Deng", "title": "Member of Scientific Advisory Board in Sales and Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}